Updated on 2025/06/13

Information

 

写真a

 
FUYUNO YOKO
 
Organization
Kyushu University Hospital Dermatology Lecturer
School of Medicine Department of Medicine(Concurrent)
Title
Lecturer
Profile
皮膚科学分野において、診療、研究、教育を行っている。
External link

Degree

Research Interests・Research Keywords

  • Research theme: dermatology

    Keyword: dermatology

    Research period: 2014.8

Papers

  • Successful control of recurrent MAS by canakinumab in a Sjögren syndrome patient with homozygous MEFV P369S variants and review of literatures

    Ono, N; Yoshimura, M; Nishida, T; Yamauchi, Y; Doi, G; Fuyuno, Y; Sonoda, M; Niiro, H

    MODERN RHEUMATOLOGY CASE REPORTS   2025.3   eISSN:2472-5625

     More details

  • Cutaneous Adverse Events Following COVID-19 Vaccination in Japan: A Questionnaire Survey.

    Yamamura Y, Nakashima C, Kagawa N, Aoyama Y, Yamamoto A, Kawahira H, Kubota Y, Nakajima S, Nakahara T, Fuyuno Y, Tsuruta D, Matsumoto A, Matsuo R, Abe R, Yuki A, Takahashi H, Takahashi C, Imafuku S, Sato E, Fujiwara S, Yasuda M, Tada Y, Hayashi K, Katoh N, Watanabe D, Otsuka A

    Cureus   17 ( 3 )   e80257   2025.3   ISSN:2168-8184

     More details

    Language:English  

    DOI: 10.7759/cureus.80257

    PubMed

  • Cytokine profile of the stratum corneum in atopic dermatitis lesions differs between the face and the trunk

    Kido-Nakahara Makiko, Chiba Takahito, Mizusawa Yuta, Higashi Yuko, Ibusuki Atsuko, Igawa Satomi, Murakami Yumi, Matsunaka Hiroshi, Kuba-Fuyuno Yoko, Tsuji Gaku, Nakahara Takeshi

    Allergology International   74 ( 2 )   222 - 232   2025   ISSN:13238930 eISSN:14401592

     More details

    Language:English   Publisher:Japanese Society of Allergology  

    <p><i>Background:</i> Atopic dermatitis (AD) is a chronic inflammatory skin disease with intense pruritus. Dupilumab, an anti-IL-4 receptor alpha antibody, has been revealed to be highly effective against the symptoms of AD; however, dupilumab takes longer to improve facial dermatitis in some patients. We thus examined whether the cytokine profiles in AD lesions differ between different anatomical locations.</p><p><i>Methods:</i> Stratum corneum was collected by tape stripping from lesions of the forehead and abdomen of 24 patients with moderate to severe AD and at the same anatomical locations of 14 control subjects. These samples were then used to determine the expression profiles of Th1, Th2, and Th17 cytokines/chemokines by multiplex assay and immunocytochemistry.</p><p><i>Results:</i> We found that cytokines/chemokines in the stratum corneum differed in their expression between different anatomical areas in AD patients and also in healthy control subjects. The expression of Th1 and Th17 cytokines/chemokines such as IP-10, MIG, and IL-17 tended to be higher in the forehead than in the abdomen in the AD group. Regarding Th2 cytokines/chemokines, some (e.g., IL-13 and IL-33) were highly expressed in the abdomen, others (e.g., IL-4 and IL-31) were highly expressed in the forehead, and a third group (e.g., TARC and TSLP) did not differ significantly in their expression between the forehead and abdomen. These patterns of Th2 cytokines were almost identical in the stratum corneum of healthy individuals.</p><p><i>Conclusions:</i> Differences in cytokine/chemokine profiles in the stratum corneum between different anatomical areas might affect the responsiveness to AD treatment.</p>

    DOI: 10.1016/j.alit.2024.08.010

    Scopus

    CiNii Research

  • Extracellular ATP Contributes to Barrier Function and Inflammation in Atopic Dermatitis: Potential for Topical Treatment of Atopic Dermatitis by Targeting Extracellular ATP

    Yamamura K., Ohno F., Yotsumoto S., Sato Y., Kimura N., Nishio K., Inoue K., Ichiki T., Kuba-Fuyuno Y., Fujishima K., Ito T., Kido-Nakahara M., Tsuji G., Nakahara T.

    International Journal of Molecular Sciences   25 ( 22 )   2024.11   ISSN:16616596

     More details

    Publisher:International Journal of Molecular Sciences  

    Atopic dermatitis (AD) is characterized by chronic inflammation, barrier dysfunction, and pruritus, exacerbated by external stimuli, such as scratching. This study investigates the role of extracellular adenosine triphosphate (ATP) in the pathophysiology of AD and assesses the therapeutic potential of clodronate, an ATP release inhibitor. Our research demonstrates that extracellular ATP impairs skin barrier function by reducing the filaggrin expression in the keratinocytes, a critical protein for barrier integrity. Furthermore, ATP release, triggered by IL-4 and mechanical stimuli, amplifies inflammation by promoting cytokine and chemokine production by the immune cells. Clodronate, by inhibiting ATP release, restores the filaggrin levels in the keratinocytes, reduces TARC production in the dendritic cells, and alleviates AD symptoms in a mouse model. These findings suggest that targeting extracellular ATP could offer a novel therapeutic approach to improving skin barrier function and reducing inflammation in AD. Future studies should explore the long-term efficacy and safety of ATP-targeted therapies in clinical settings.

    DOI: 10.3390/ijms252212294

    Scopus

  • Proposal of a cutaneous lupus erythematosus-like keratinocyte model in vitro under local conditions using interferon-alpha and Poly I:C and its use in examining the therapeutic effects of tyrosine kinase 2 inhibitor

    Kuba-Fuyuno Y., Kido-Nakahara M., Tsuji G., Sakai S., Nakahara T.

    Journal of Dermatology   51 ( 7 )   1031 - 1033   2024.7   ISSN:03852407

     More details

    Publisher:Journal of Dermatology  

    DOI: 10.1111/1346-8138.17318

    Scopus

  • Eccrine Angiomatous Hamartoma : Three Case Report

    MIZUNO Ami, KUMA Yuki, FUYUNO Yoko, KIDO-NAKAHARA Makiko, TSUJI Gaku, NAKAHARA Takeshi, KIRYU Hiromaro

    The Nishinihon Journal of Dermatology   84 ( 6 )   547 - 551   2022.12   ISSN:03869784 eISSN:18804047

     More details

    Language:Japanese   Publisher:Western Division of Japanese Dermatological Association  

    <p>我々は,異なる臨床像を呈した 3 例の Eccrine Angiomatous Hamartoma(EAH)を経験した。症例 1: 78 歳,男性。幼少期から右肘窩部に暗赤色腫瘤を自覚し,緩徐に増大傾向であった。症例 2:41 歳,男性。10 年前から左頰部に淡青灰色局面を自覚していた。局面の大きさは 10 年でほぼ変わりなかった。症例 3:41 歳,女性。8 年前から上腹部に皮下腫瘤を自覚し,2 カ月前から疼痛を伴うようになった。症例 1 と 3 は全切除生検,症例 2 は部分生検を行った。3 症例とも病理組織学的に腫瘍の境界は不明瞭で,真皮にエクリン汗腺や小血管の増生を認め,EAH と診断した。 EAH は比較的まれな腫瘍であり,多彩な臨床像をとる。自験例は初診時に鑑別疾患として EAH は挙がらず,病理組織学的検査で診断がついた。疾患に特徴的な画像所見もこれまで報告されておらず,診断には発症時期や局所多汗などの特徴的な所見を問診することと,皮膚生検が有用と考える。</p>

    DOI: 10.2336/nishinihonhifu.84.547

    Scopus

    CiNii Research

  • Eccrine Angiomatous Hamartomaの3例

    水野 亜美, 隈 有希, 冬野 洋子, 中原 真希子, 辻 学, 中原 剛士, 桐生 美麿

    西日本皮膚科   84 ( 6 )   547 - 551   2022.12   ISSN:0386-9784

     More details

    Language:Japanese   Publisher:日本皮膚科学会-西部支部  

    我々は,異なる臨床像を呈した3例のEccrine Angiomatous Hamartoma(EAH)を経験した。症例1:78歳,男性。幼少期から右肘窩部に暗赤色腫瘤を自覚し,緩徐に増大傾向であった。症例2:41歳,男性。10年前から左頬部に淡青灰色局面を自覚していた。局面の大きさは10年でほぼ変わりなかった。症例3:41歳,女性。8年前から上腹部に皮下腫瘤を自覚し,2ヵ月前から疼痛を伴うようになった。症例1と3は全切除生検,症例2は部分生検を行った。3症例とも病理組織学的に腫瘍の境界は不明瞭で,真皮にエクリン汗腺や小血管の増生を認め,EAHと診断した。EAHは比較的まれな腫瘍であり,多彩な臨床像をとる。自験例は初診時に鑑別疾患としてEAHは挙がらず,病理組織学的検査で診断がついた。疾患に特徴的な画像所見もこれまで報告されておらず,診断には発症時期や局所多汗などの特徴的な所見を問診することと,皮膚生検が有用と考える。(著者抄録)

  • Nuchal-type Fibroma

    SASAKI Natsuki, FUYUNO Yoko, FURUE Masutaka

    Nishi Nihon Hifuka   84 ( 1 )   5 - 6   2022.2   ISSN:03869784 eISSN:18804047

     More details

    Language:Japanese   Publisher:Western Division of Japanese Dermatological Association  

    <p><b>患者</b>:74 歳,男性</p><p><b>主訴</b>:後頭部の皮下腫瘤</p><p><b>既往歴</b>:Triple extramammary Paget's 病,菌状息肉症</p><p><b>家族歴</b>:特記事項なし</p><p><b>現病歴</b>:初診の 10 年前に後頭部に皮下腫瘤を認め,近医で切開された。最近,同部位に皮下腫瘤を認め,当科を受診した。</p><p><b>初診時現症</b>:後頭部に境界不明瞭な約 2 cm の弾性硬で可動性良好な皮下腫瘤を触知した(<b>図 1 </b>)。</p><p><b>超音波検査所見</b>:皮下に低エコー領域を認め,後方エコーの減弱を認めた(<b>図 2 </b>)。</p><p><b>病理組織学的所見</b>:真皮から皮下にかけて境界不明瞭に錯綜する不規則な膠原線維と,それに取り囲まれた島状の脂肪組織と神経線維を認め,線維芽細胞は目立たなかった(<b>図 3 </b>)。膠原線維間の紡錘形細胞,および星芒状細胞は CD34 陽性で,異型は認めなかった(<b>図 4 </b>)。</p><p><b>診断</b>:Nuchal-type fibroma(NTF)</p>

    DOI: 10.2336/nishinihonhifu.84.5

    CiNii Research

▼display all

Presentations

▼display all

MISC

Professional Memberships

  • 日本皮膚科学会

  • 日本アレルギー学会

  • 日本皮膚免疫アレルギー学会

  • 日本研究皮膚科学会

Research Projects

  • AHR agonistによるSLE皮疹の新たな治療薬の開発

    Grant number:24K19176  2024 - 2026

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Early-Career Scientists

    冬野 洋子

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    全身性エリテマトーデス(SLE)の治療は、これまでステロイド内服などの免疫抑制剤が治療の主体であったが、近年ステロイドを減薬させることができるような、長期的に安全な新規治療薬の開発が望まれている。炎症性皮膚疾患の新たな治療ターゲットとして、AHR(Aryl hydrocarbon receptor; 芳香族炭化水素受容体)が注目されている。本研究ではAHRをターゲットとしたSLE皮疹に対する新たな治療法の開発を目指す。

    CiNii Research

  • Novel therapy targeting autophagy/LAP balance in SLE skin eruption

    Grant number:22K16265  2022 - 2023

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Early-Career Scientists

    Fuyuno Yoko

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    The activation kinetics of the AHR, NRF2, and EGFR pathways were examined in NHEK when autophagy was induced, inhibited, or LAP inhibited. It was determined that CYP1A1 tended to increase regardless of autophagy/LAP, which may be due to reagent characteristics, and that autophagy/LAP balance and activation of the AHR could not be evaluated with autophagy inducers/inhibitors or LAP inhibitors. Stimulation of keratinocytes with synthetic nucleic acid and IFNα resulted in the appearance of SLE skin rash-like signals. Further treatment with AHR ligand showed suppression of some of the above SLE-like skin rash signals.

    CiNii Research

Educational Activities

  • 皮膚科レジデント、医学部学生およびローテート研修医に指導を行う。

Class subject

  • 生理機能検査学

    2023.4 - 2023.9   First semester

  • 臨床医学基本実習

    2023.4 - 2023.9   First semester

  • 臨床医学論Ⅱ

    2022.10 - 2023.3   Second semester

  • 患者実習

    2014.10 - 2015.3   Second semester

  • 皮膚科学

    2014.10 - 2015.3   Second semester

  • 生理学

    2014.4 - 2014.9   First semester

▼display all

Outline of Social Contribution and International Cooperation activities

  • 全国油症治療研究班が主催する会議や油症対策委員会に出席し、油症患者との意見交換を行う。

Social Activities

  • 特記なし

    2023

     More details

    特記なし